Carboplatin and weekly paclitaxel in combination with bevacizumab for the treatment of advanced non-small cell lung cancer complicated by idiopathic interstitial pneumonias : A feasibility study
Copyright © 2023 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved..
BACKGROUND: Idiopathic interstitial pneumonias are an independent risk factor of lung cancer, and a chemotherapy-induced acute exacerbation is the most common lethal complication in Japanese patients. The safety and efficacy of carboplatin and weekly paclitaxel for the treatment of non-small cell lung cancer with idiopathic interstitial pneumonias has been previously reported in prospective studies. However, carboplatin + paclitaxel with bevacizumab is currently the standard therapy. We conducted a multicenter, phase II study to confirm the safety and efficacy of carboplatin + weekly paclitaxel + bevacizumab for the treatment of patients with lung cancer complicated by idiopathic interstitial pneumonias.
METHODS: Chemotherapy-naïve patients with advanced-stage or patients with post-operative recurrent non-squamous non-small cell lung cancer complicated by idiopathic interstitial pneumonias were enrolled. Patients received carboplatin (area under the curve: 5.0) and bevacizumab (15 mg/kg) on day 1 and paclitaxel (100 mg/m2) on days 1, 8, and 15 of each 4-week cycle.
RESULTS: Seventeen patients less than the predetermined number were enrolled and received a median of four treatment cycles (range: 1-6). One patient (5.9%; 95% confidence interval: 0.1-28.7%) had acute exacerbation of interstitial pneumonia related to the study treatment which improved after corticosteroid treatment. The overall response rate was 52.9%. The median progression-free survival, median survival time, and 1-year survival were 5.7 months, 12.9 months, and 52.9%, respectively.
CONCLUSION: The addition of bevacizumab to carboplatin and weekly paclitaxel might be safe and effective for the treatment of advanced non-small cell lung cancer complicated by idiopathic interstitial pneumonias.
CLINICAL TRIAL REGISTRATION NUMBER: UMIN000008189.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Respiratory investigation - 61(2023), 5 vom: 01. Sept., Seite 625-631 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Omori, Miwako [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.08.2023 Date Revised 21.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.resinv.2023.06.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359426824 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359426824 | ||
| 003 | DE-627 | ||
| 005 | 20231226080843.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.resinv.2023.06.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1198.xml |
| 035 | |a (DE-627)NLM359426824 | ||
| 035 | |a (NLM)37441903 | ||
| 035 | |a (PII)S2212-5345(23)00060-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Omori, Miwako |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Carboplatin and weekly paclitaxel in combination with bevacizumab for the treatment of advanced non-small cell lung cancer complicated by idiopathic interstitial pneumonias |b A feasibility study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.08.2023 | ||
| 500 | |a Date Revised 21.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Idiopathic interstitial pneumonias are an independent risk factor of lung cancer, and a chemotherapy-induced acute exacerbation is the most common lethal complication in Japanese patients. The safety and efficacy of carboplatin and weekly paclitaxel for the treatment of non-small cell lung cancer with idiopathic interstitial pneumonias has been previously reported in prospective studies. However, carboplatin + paclitaxel with bevacizumab is currently the standard therapy. We conducted a multicenter, phase II study to confirm the safety and efficacy of carboplatin + weekly paclitaxel + bevacizumab for the treatment of patients with lung cancer complicated by idiopathic interstitial pneumonias | ||
| 520 | |a METHODS: Chemotherapy-naïve patients with advanced-stage or patients with post-operative recurrent non-squamous non-small cell lung cancer complicated by idiopathic interstitial pneumonias were enrolled. Patients received carboplatin (area under the curve: 5.0) and bevacizumab (15 mg/kg) on day 1 and paclitaxel (100 mg/m2) on days 1, 8, and 15 of each 4-week cycle | ||
| 520 | |a RESULTS: Seventeen patients less than the predetermined number were enrolled and received a median of four treatment cycles (range: 1-6). One patient (5.9%; 95% confidence interval: 0.1-28.7%) had acute exacerbation of interstitial pneumonia related to the study treatment which improved after corticosteroid treatment. The overall response rate was 52.9%. The median progression-free survival, median survival time, and 1-year survival were 5.7 months, 12.9 months, and 52.9%, respectively | ||
| 520 | |a CONCLUSION: The addition of bevacizumab to carboplatin and weekly paclitaxel might be safe and effective for the treatment of advanced non-small cell lung cancer complicated by idiopathic interstitial pneumonias | ||
| 520 | |a CLINICAL TRIAL REGISTRATION NUMBER: UMIN000008189 | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute exacerbation | |
| 650 | 4 | |a Bevacizumab | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Idiopathic interstitial pneumonia | |
| 650 | 4 | |a Non-squamous cell carcinoma | |
| 650 | 7 | |a Carboplatin |2 NLM | |
| 650 | 7 | |a BG3F62OND5 |2 NLM | |
| 650 | 7 | |a Paclitaxel |2 NLM | |
| 650 | 7 | |a P88XT4IS4D |2 NLM | |
| 650 | 7 | |a Bevacizumab |2 NLM | |
| 650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
| 700 | 1 | |a Minegishi, Yuji |e verfasserin |4 aut | |
| 700 | 1 | |a Uruga, Hironori |e verfasserin |4 aut | |
| 700 | 1 | |a Fukuizumi, Aya |e verfasserin |4 aut | |
| 700 | 1 | |a Isobe, Kazutoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Izumi, Shinyu |e verfasserin |4 aut | |
| 700 | 1 | |a Koyama, Ryo |e verfasserin |4 aut | |
| 700 | 1 | |a Bando, Masashi |e verfasserin |4 aut | |
| 700 | 1 | |a Sugiyama, Haruhito |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Kazuhisa |e verfasserin |4 aut | |
| 700 | 1 | |a Gemma, Akihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Homma, Sakae |e verfasserin |4 aut | |
| 700 | 1 | |a Sugiyama, Yukihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kishi, Kazuma |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory investigation |d 2012 |g 61(2023), 5 vom: 01. Sept., Seite 625-631 |w (DE-627)NLM217493343 |x 2212-5353 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2023 |g number:5 |g day:01 |g month:09 |g pages:625-631 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.resinv.2023.06.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2023 |e 5 |b 01 |c 09 |h 625-631 | ||